These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30824185)

  • 1. Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.
    Ito T; Kumagai Y; Itano K; Maruyama T; Tamura K; Kawasaki S; Suzuki T; Murakami Y
    Biochem Biophys Res Commun; 2019 Apr; 511(3):544-550. PubMed ID: 30824185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
    Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib.
    Jin Q; Zheng J; Chen M; Jiang N; Xu X; Huang F
    Oxid Med Cell Longev; 2021; 2021():6633867. PubMed ID: 33763171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Engelman JA; Zejnullahu K; Mitsudomi T; Song Y; Hyland C; Park JO; Lindeman N; Gale CM; Zhao X; Christensen J; Kosaka T; Holmes AJ; Rogers AM; Cappuzzo F; Mok T; Lee C; Johnson BE; Cantley LC; Jänne PA
    Science; 2007 May; 316(5827):1039-43. PubMed ID: 17463250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
    Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
    Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.
    Li Y; Zhang R; Zhou Y; Song J; Luo W; Tian P; Li W
    Clin Lung Cancer; 2019 May; 20(3):e251-e255. PubMed ID: 30638795
    [No Abstract]   [Full Text] [Related]  

  • 12. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
    Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma.
    Huang Z; Ma Y; Zhang P; Si J; Xiong Y; Yang Y
    Anticancer Drugs; 2020 Jan; 31(1):44-54. PubMed ID: 31503013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
    Li YQ; Liu YS; Ying XW; Zhou HB; Wang Z; Wu SC; Yan JP; Jing YT; Yang Y
    Biotechnol Prog; 2018 Jan; 34(1):196-205. PubMed ID: 28960861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
    Wang Y; Zhang W; Wen L; Yang H; Wen M; Yun Y; Zhao L; Zhu X; Tian L; Luo E; Li Y; Liu W; Wen N
    Oncotarget; 2016 Sep; 7(37):59245-59259. PubMed ID: 27494877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
    Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
    Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.